NASDAQ · FTRE
Fortrea Holdings Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for FTRE has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.23 | $0.25 | $0.22 | 2 |
| Mar 2027 | $0.23 | $0.26 | $0.19 | 2 |
| Jun 2027 | $0.28 | $0.31 | $0.24 | 2 |
| Sep 2027 | $0.33 | $0.37 | $0.29 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Fintel · Zacks · RTTNews- The Motley Fool · Oct 29, 1:44 PM EDTFortrea (FTRE) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 29, 9:54 AM EDTFortrea Holdings Inc. Reports Third Quarter 2026 Financial Results and Updates Full-Year GuidanceFortrea Holdings Inc. reported its financial results for the third quarter ended September 30, 2026. Revenue for the quarter was $691.5 million, compared to $701.3 million in the third quarter of 2025. GAAP net income was $0.6 million, or $0.01 per diluted share, compared to a GA
- Zacks · Oct 29, 6:45 AM EDTFortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass EstimatesFortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +16.67% and +3.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 26, 9:00 AM EDTVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 22, 9:00 AM EDTFortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 20, 1:51 AM EDTFortrea Completes $45 Mln Acquisition Of Worldwide's Early Phase Services Divisions(RTTNews) – Fortrea Holdings Inc. (FTRE), a global contract research organization (CRO), announced the completion of its $45 million all-cash acquisition of the Early Phase Services division of Worldwide Clinical Trials.
- RTTNews · Oct 7, 7:25 AM EDTBiotech Stocks At 52-Week Highs – PACB, FTRE, ALMR, TXG, AZTA(RTTNews) – The following biotech stocks reached a 52-week high on October 6, 2026, driven by key catalysts such as newly announced research collaborations.
- RTTNews · Sep 2, 10:16 AM EDTFortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up(RTTNews) – Fortrea Holdings Inc. (FTRE) announced that it has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials, which includes its Clinical Pharmacology Unit and Bioanalytical Laboratory operations.
- RTTNews · Sep 2, 9:05 AM EDTFortrea To Acquire Early Phase Services Business From Worldwide In Deal Valued At Approx. $45 Mln(RTTNews) – Fortrea (FTRE) and Worldwide Clinical Trials announced that they have signed a definitive agreement under which Fortrea will acquire Worldwide's Early Phase Services division, consisting of its Clinical Pharmacology Unit and Bioanalytical Laboratory operations. Fortre
- The Motley Fool · Aug 7, 8:58 PM EDTFortrea (FTRE) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 6, 11:29 AM EDTIs ICON a Buy as Valuation Improves but Earnings Risks Still Persist?ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
- Zacks · Aug 4, 11:58 AM EDTWhy IQVIA Stock Jumped 13% in a Week and Whether the Gains Can LastIQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Fortrea Holdings Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.